Lucid Diagnostics Inc. (LUCD) Stock Overview
Explore Lucid Diagnostics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Lucid Diagnostics Inc. (LUCD)
Key Financials
Key Financials
Market Cap
184.1M
P/E Ratio
-2.11
EPS (TTM)
$-0.37
ROE
-0.02%
LUCD Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Lucid Diagnostics Inc. (NASDAQ: LUCD) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Lucid Diagnostics Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of LUCD on the NASDAQ shows an RSI of 51.51, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.97 for the NASDAQ listing.
Key metrics behind Lucid Diagnostics Inc.'s NASDAQ-traded stock include a P/E ratio of -2.11 and a market capitalization of 184.1M. Combined with our AI analysis, these give both institutional and retail investors a clear view of LUCD on the NASDAQ.